Genertec Universal Medical Group Company Limited

As of December 31, 2025, Genertec Universal Medical Group Company Limited carries a market capitalization of 11.98B, placing it among publicly traded companies globally. Its enterprise value stands at 72.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genertec Universal Medical Group Company Limited's next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2025, Genertec Universal Medical Group Company Limited has 2.01B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Genertec Universal Medical Group Company Limited maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Genertec Universal Medical Group Company Limited's stock has declined approximately 27.32% over the past 52 weeks. The 50-day moving average sits at 4.56, while the 200-day moving average is 5.31.

As of December 31, 2025, Genertec Universal Medical Group Company Limited holds 2.36B in cash and equivalents against 58.69B in total debt, resulting in a net debt position of 50.72B. Total book value stands at 23.31B, with working capital of 10.73B providing operational flexibility.